QTRX

SEC source: 0001562180-19-005513 · primarydocument.xml · nonDerivative · entry 6

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 220,366

F1 · kind: All sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person on September 9, 2019.

F5 · price: This transaction was executed in multiple trades at prices ranging from $21.39 to $22.12. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4 · ownership.nature: Held by a trust for which the Reporting Person is a trust advisor who shares voting and investment control.

SEC source: 0001562180-19-005513 · primarydocument.xml · nonDerivative · entry 5

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,549

F1 · kind: All sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person on September 9, 2019.

SEC source: 0001562180-19-005513 · primarydocument.xml · nonDerivative · entry 4

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-005513 · primarydocument.xml · derivative · entry 7

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,707

Underlying: Common Stock · 1,600 shares

Expires 2021-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: All options are vested and exercisable.

SEC source: 0001562180-19-005513 · primarydocument.xml · nonDerivative · entry 3

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 222,666

F1 · kind: All sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person on September 9, 2019.

F3 · price: This transaction was executed in multiple trades at prices ranging from $21.98 to $22.67. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4 · ownership.nature: Held by a trust for which the Reporting Person is a trust advisor who shares voting and investment control.

SEC source: 0001562180-19-005513 · primarydocument.xml · nonDerivative · entry 2

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,549

F1 · kind: All sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person on September 9, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $22.26 to $22.34. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-005513 · primarydocument.xml · nonDerivative · entry 1

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-005324 · primarydocument.xml · nonDerivative · entry 1

HRUSOVSKY E KEVIN · CIK 0001252546 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,170,520

F1 · shares: The sales of shares reported on this Form 4 was made solely to cover tax obligations upon the vesting of 7,123 RSUs.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.79 to $20.92. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 39,815 shares of common stock that are subject to performance based vesting and 196,119 restricted stock units.

SEC source: 0001562180-19-005326 · primarydocument.xml · nonDerivative · entry 1

Roskey Mark T. · CIK 0001724565 · SVP, Commercial & Accelerator

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,397

F1 · shares: The sales of shares reported on this Form 4 was made solely to cover tax obligations upon the vesting of 148 RSUs.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.79 to $20.92. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 11,689 restricted stock units.

SEC source: 0001562180-19-005325 · primarydocument.xml · nonDerivative · entry 1

Mattoon Dawn · CIK 0001731785 · Sr. VP, Research Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,471

F1 · shares: The sales of shares reported on this Form 4 were made solely to cover tax obligations upon the vesting of 368 RSUs.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.79 to $20.92. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 17,656 restricted stock units.

SEC source: 0001562180-19-005204 · primarydocument.xml · derivative · entry 3

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,275

Underlying: Common Stock · 1,667 shares

Expires 2021-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option is fully vested.

SEC source: 0001562180-19-005204 · primarydocument.xml · nonDerivative · entry 2

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,760

F1 · shares: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.28 to $20.36. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 9,177 restricted stock units.

SEC source: 0001562180-19-005204 · primarydocument.xml · nonDerivative · entry 1

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-005048 · primarydocument.xml · nonDerivative · entry 1

HRUSOVSKY E KEVIN · CIK 0001252546 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,173,856

F1 · shares: The sales of shares reported on this Form 4 was made solely to cover tax obligations upon the vesting of 7,123 RSUs.

F2 · balance_after: Includes 39,815 shares of common stock that are subject to performance based vesting and 203,242 restricted stock units.

SEC source: 0001562180-19-005049 · primarydocument.xml · nonDerivative · entry 1

Mattoon Dawn · CIK 0001731785 · Sr. VP, Research Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,586

F1 · shares: The sales of shares reported on this Form 4 were made solely to cover tax obligations upon the vesting of 368 RSUs.

F2 · balance_after: Includes 18,024 restricted stock units.

SEC source: 0001562180-19-005050 · primarydocument.xml · nonDerivative · entry 1

Roskey Mark T. · CIK 0001724565 · SVP, Commercial & Accelerator

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,443

F1 · shares: The sales of shares reported on this Form 4 was made solely to cover tax obligations upon the vesting of 148 RSUs.

F2 · balance_after: Includes 11,837 restricted stock units.

SEC source: 0001562180-19-005099 · primarydocument.xml · nonDerivative · entry 1

MEISTER PAUL M · CIK 0001033876 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,157

F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2019, pursuant to an election made in December 2018.

F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 1, 2019.

F3 · balance_after: Includes 2,270 restricted stock units.

SEC source: 0001562180-19-005098 · primarydocument.xml · nonDerivative · entry 1

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,549

F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2019, pursuant to an election made in December 2018.

F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 1, 2019.

F3 · balance_after: Includes 2,270 restricted stock units.

SEC source: 0001562180-19-005106 · primarydocument.xml · nonDerivative · entry 1

Hlavinka Sarah E. · CIK 0001433554 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,860

F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2019, pursuant to an election made in July 2019.

F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 1, 2019.

F3 · balance_after: Includes 4,540 restricted stock units.

SEC source: 0001562180-19-005097 · primarydocument.xml · nonDerivative · entry 1

CRANDELL KEITH · CIK 0001219039 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,922

F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2019, pursuant to an election made in December 2018.

F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 1, 2019.

F3 · balance_after: Includes 2,270 restricted stock units.

SEC source: 0001562180-19-004848 · primarydocument.xml · derivative · entry 3

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,942

Underlying: Common Stock · 1,667 shares

Expires 2021-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option is fully vested.

SEC source: 0001562180-19-004848 · primarydocument.xml · nonDerivative · entry 2

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,760

F1 · shares: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2019.

F2 · balance_after: Includes 9,291 restricted stock units.

SEC source: 0001562180-19-004848 · primarydocument.xml · nonDerivative · entry 1

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-004671 · primarydocument.xml · nonDerivative · entry 1

HRUSOVSKY E KEVIN · CIK 0001252546 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,177,192

F1 · shares: The sales of shares reported on this Form 4 was made solely to cover tax obligations upon the vesting of 7,123 RSUs.

F2 · price: This transaction was executed in multiple trades at prices ranging from $25.92 to $26.085. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 39,815 shares of common stock that are subject to performance based vesting and 210,365 restricted stock units.

SEC source: 0001562180-19-004673 · primarydocument.xml · nonDerivative · entry 1

Roskey Mark T. · CIK 0001724565 · SVP, Commercial & Accelerator

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,489

F1 · shares: The sales of shares reported on this Form 4 was made solely to cover tax obligations upon the vesting of 148 RSUs.

F2 · price: This transaction was executed in multiple trades at prices ranging from $25.92 to $26.085. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 435 shares acquired under the Quanterix Corporation Employee Stock Purchase Plan on August 30, 2019. Also includes 11,985 restricted stock units.

SEC source: 0001562180-19-004672 · primarydocument.xml · nonDerivative · entry 1

Mattoon Dawn · CIK 0001731785 · Sr. VP, Research Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,701

F1 · shares: The sales of shares reported on this Form 4 were made solely to cover tax obligations upon the vesting of 368 RSUs.

F2 · price: This transaction was executed in multiple trades at prices ranging from $25.92 to $26.085. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 18,392 restricted stock units.

SEC source: 0001562180-19-005710 · primarydocument.xml · nonDerivative · entry 1

Roskey Mark T. · CIK 0001724565 · SVP, Commercial & Accelerator

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,424

F1 · shares: The sales of shares reported on this Form 4 was made solely to cover tax obligations upon the vesting of 148 RSUs.

F2 · price: This transaction was executed in multiple trades at prices ranging from $25.92 to $26.085. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 370 shares acquired under the Quanterix Corporation Employee Stock Purchase Plan on August 30, 2019. Also includes 11,985 restricted stock units. This amendment has been filed to correct an error in the number of shares acquired under the Quanterix Corporation Employee Stock Pension Plan on August 30, 2019.

SEC source: 0001562180-19-004479 · primarydocument.xml · nonDerivative · entry 1

HRUSOVSKY E KEVIN · CIK 0001252546 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,180,554

F1 · kind: The sales of shares reported on this Form 4 was made solely to cover tax obligations upon the vesting of 1,061 RSUs.

F2 · balance_after: Includes 39,815 shares of common stock that are subject to performance based vesting and 217,488 restricted stock units.

SEC source: 0001104659-19-046955 · a4.xml · nonDerivative · entry 2

DEKKERS MARIJN E · CIK 0001216068 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,540

F1 · kind: On August 20, 2019, the Reporting Person transferred an aggregate of 117,378 shares of common stock of Quanterix Corporation (the "Issuer") to Novalis LifeSciences Investments I, L.P (the "Fund"). As the sole member of Novalis LifeSciences Investments I GP, LLC, the general partner of the Fund, the Reporting Person continues to have sole voting and investment control over all of the shares transferred to the Fund. Of the 117,378 shares transferred to the Fund, the Reporting Person's pecuniary interest with respect to 27,619 of the shares did not change. This Form 4 is filed to report the transfer of 89,759 of the shares to the Fund over which the Reporting Person continues to have voting and investment control, but not a pecuniary interest. The shares were transferred to the Fund based on the prices at which the Reporting Person originally purchased the shares from the Issuer.

F1 · price: On August 20, 2019, the Reporting Person transferred an aggregate of 117,378 shares of common stock of Quanterix Corporation (the "Issuer") to Novalis LifeSciences Investments I, L.P (the "Fund"). As the sole member of Novalis LifeSciences Investments I GP, LLC, the general partner of the Fund, the Reporting Person continues to have sole voting and investment control over all of the shares transferred to the Fund. Of the 117,378 shares transferred to the Fund, the Reporting Person's pecuniary interest with respect to 27,619 of the shares did not change. This Form 4 is filed to report the transfer of 89,759 of the shares to the Fund over which the Reporting Person continues to have voting and investment control, but not a pecuniary interest. The shares were transferred to the Fund based on the prices at which the Reporting Person originally purchased the shares from the Issuer.

F2 · balance_after: Includes 2,270 restricted stock units.

SEC source: 0001104659-19-046955 · a4.xml · nonDerivative · entry 1

DEKKERS MARIJN E · CIK 0001216068 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,128

F1 · kind: On August 20, 2019, the Reporting Person transferred an aggregate of 117,378 shares of common stock of Quanterix Corporation (the "Issuer") to Novalis LifeSciences Investments I, L.P (the "Fund"). As the sole member of Novalis LifeSciences Investments I GP, LLC, the general partner of the Fund, the Reporting Person continues to have sole voting and investment control over all of the shares transferred to the Fund. Of the 117,378 shares transferred to the Fund, the Reporting Person's pecuniary interest with respect to 27,619 of the shares did not change. This Form 4 is filed to report the transfer of 89,759 of the shares to the Fund over which the Reporting Person continues to have voting and investment control, but not a pecuniary interest. The shares were transferred to the Fund based on the prices at which the Reporting Person originally purchased the shares from the Issuer.

F1 · price: On August 20, 2019, the Reporting Person transferred an aggregate of 117,378 shares of common stock of Quanterix Corporation (the "Issuer") to Novalis LifeSciences Investments I, L.P (the "Fund"). As the sole member of Novalis LifeSciences Investments I GP, LLC, the general partner of the Fund, the Reporting Person continues to have sole voting and investment control over all of the shares transferred to the Fund. Of the 117,378 shares transferred to the Fund, the Reporting Person's pecuniary interest with respect to 27,619 of the shares did not change. This Form 4 is filed to report the transfer of 89,759 of the shares to the Fund over which the Reporting Person continues to have voting and investment control, but not a pecuniary interest. The shares were transferred to the Fund based on the prices at which the Reporting Person originally purchased the shares from the Issuer.

F2 · balance_after: Includes 2,270 restricted stock units.

SEC source: 0001562180-19-004402 · primarydocument.xml · derivative · entry 3

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,609

Underlying: Common Stock · 1,667 shares

Expires 2021-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option is fully vested.

SEC source: 0001562180-19-004402 · primarydocument.xml · nonDerivative · entry 2

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,760

F1 · shares: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.91 to $28.08. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 9,405 restricted stock units.

SEC source: 0001562180-19-004402 · primarydocument.xml · nonDerivative · entry 1

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-19-046813 · a4.xml · derivative · entry 2

Desjourdy Amee · CIK 0001785452 · Chief Human Resource Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,354

Underlying: Common Stock · 17,354 shares

Expires 2029-08-19

F2 · derivative.exercise_date: The option vests as to 25% of the shares on August 19, 2020 and vests as to an additional 2.083% of the shares per month at the end of each month for 36 months thereafter beginning August 31, 2020, subject to certain accelerated vesting provisions upon a sale of the company within 18 months of the grant date.

SEC source: 0001104659-19-046813 · a4.xml · nonDerivative · entry 1

Desjourdy Amee · CIK 0001785452 · Chief Human Resource Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,834

F1 · shares: Represents shares of common stock issuable upon vesting of restricted stock units. The restricted stock units vest as to 25% of the shares on August 19, 2020 and vest as to an additional 2.083% of the shares per month at the end of each month for 36 months thereafter beginning August 31, 2020, subject to certain accelerated vesting provisions upon a sale of the company within 18 months of the grant date.

SEC source: 0001562180-19-004401 · primarydocument.xml · derivative · entry 2

HRUSOVSKY E KEVIN · CIK 0001252546 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2029-08-17

F3 · derivative.exercise_date: The option vested as to 4,166 shares immediately upon grant, and vests as to an additional 833.333 shares at the end of each month thereafter starting on August 31, 2019 for 43 months, subject to Mr. Hrusovsky's continued service as Chief Executive Officer.

SEC source: 0001562180-19-004401 · primarydocument.xml · nonDerivative · entry 1

HRUSOVSKY E KEVIN · CIK 0001252546 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,181,077

F1 · shares: Represents shares of common stock issuable upon vesting of restricted stock units. The restricted stock units vested as to 1,061 shares immediately upon grant, and vest as to an additional 212.375 shares at the end of each month thereafter starting on August 31, 2019 for 43 months, subject to Mr. Hrusovsky's continued service as Chief Executive Officer.

F2 · balance_after: Includes 39,815 shares of common stock that are subject to performance based vesting and 218,549 restricted stock units.

SEC source: 0001562180-19-004148 · primarydocument.xml · nonDerivative · entry 2

HRUSOVSKY E KEVIN · CIK 0001252546 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,170,883

F1 · shares: The sales of shares reported on this Form 4 was made solely to cover tax obligations upon the vesting of 6,250 RSUs and 661 RSUs, respectively.

F2 · price: This transaction was executed in multiple trades at prices ranging from $31.55 to $31.795. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-004148 · primarydocument.xml · nonDerivative · entry 1

HRUSOVSKY E KEVIN · CIK 0001252546 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,171,186

F1 · shares: The sales of shares reported on this Form 4 was made solely to cover tax obligations upon the vesting of 6,250 RSUs and 661 RSUs, respectively.

F2 · price: This transaction was executed in multiple trades at prices ranging from $31.55 to $31.795. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 39,815 shares of common stock that are subject to performance based vesting and 208,355 restricted stock units.

SEC source: 0001562180-19-004147 · primarydocument.xml · nonDerivative · entry 1

Roskey Mark T. · CIK 0001724565 · SVP, Commercial & Accelerator

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,101

F1 · shares: The sale of shares reported on the Form 4 was made solely to cover tax obligations upon the vesting of 148 RSUs.

F2 · price: This transaction was executed in multiple trades at prices ranging from $31.55 to $31.795. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 12,133 restricted stock units.

SEC source: 0001562180-19-004146 · primarydocument.xml · nonDerivative · entry 2

Mattoon Dawn · CIK 0001731785 · Sr. VP, Research Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,816

F1 · shares: The sales of shares reported on this Form 4 were made solely to cover tax obligations upon the vesting of 160 RSUs and 208 RSUs, respectively, and were effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2018.

F2 · price: This transaction was executed in multiple trades at prices ranging from $31.55 to $31.795. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 18,760 restricted stock units.

SEC source: 0001562180-19-004146 · primarydocument.xml · nonDerivative · entry 1

Mattoon Dawn · CIK 0001731785 · Sr. VP, Research Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,880

F1 · shares: The sales of shares reported on this Form 4 were made solely to cover tax obligations upon the vesting of 160 RSUs and 208 RSUs, respectively, and were effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2018.

F2 · price: This transaction was executed in multiple trades at prices ranging from $31.55 to $31.795. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001104659-19-041922 · a4.xml · derivative · entry 2

Hlavinka Sarah E. · CIK 0001433554 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,800

Underlying: Common Stock · 15,800 shares

Expires 2029-07-25

F1 · shares: Initial equity grant under the Quanterix Corporation 2018 Non-Employee Director Compensation Policy upon Ms. Hlavinka's election to the Quanterix Board of Directors.

F3 · derivative.exercise_date: The option vests as to one-third of the shares on July 25, 2020, and the remaining two-thirds of the shares over the following two years in 24 successive equal monthly installments at the end of each month until July 25, 2022.

SEC source: 0001104659-19-041922 · a4.xml · nonDerivative · entry 1

Hlavinka Sarah E. · CIK 0001433554 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,540

F1 · shares: Initial equity grant under the Quanterix Corporation 2018 Non-Employee Director Compensation Policy upon Ms. Hlavinka's election to the Quanterix Board of Directors.

F2 · shares: Represents shares of common stock issuable upon vesting of restricted stock units. The restricted stock units vest as to one-third of the shares on each of July 25, 2020, July 25, 2021 and July 25, 2022.

SEC source: 0001562180-19-003937 · primarydocument.xml · derivative · entry 3

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,276

Underlying: Common Stock · 1,667 shares

Expires 2021-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option is fully vested.

SEC source: 0001562180-19-003937 · primarydocument.xml · nonDerivative · entry 2

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,760

F1 · shares: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $29.42 to $29.7312. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 9,519 restricted stock units.

SEC source: 0001562180-19-003937 · primarydocument.xml · nonDerivative · entry 1

Duffy David C. · CIK 0001724566 · SVP R&D and CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-003859 · primarydocument.xml · nonDerivative · entry 1

MEISTER PAUL M · CIK 0001033876 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,515

F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the second quarter of 2019, pursuant to an election made in December 2018.

F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on July 1, 2019.

F3 · balance_after: Includes 2,270 restricted stock units.

SEC source: 0001562180-19-003858 · primarydocument.xml · nonDerivative · entry 1

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,737

F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the second quarter of 2019, pursuant to an election made in December 2018.

F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on July 1, 2019.

F3 · balance_after: Includes 2,270 restricted stock units.

SEC source: 0001562180-19-003857 · primarydocument.xml · nonDerivative · entry 1

CRANDELL KEITH · CIK 0001219039 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,374

F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the second quarter of 2019, pursuant to an election made in December 2018.

F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on July 1, 2019.

F3 · balance_after: Includes 2,270 restricted stock units.